Advisors Preferred’s VanEck Pharmaceutical ETF PPH Stock Holding History

Advisors Preferred’s Portfolio PPH Stock Details PPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-5,873	Closed	-$555K	–	262
2024 Q3	$555K	Buy	+5,873	New	+$558K	0.08%	109
2023 Q2	–	Sell	-424	Closed	-$32.9K	–	239
2023 Q1	$32.9K	Sell	424 -1,183	-74%	-$91.2K	0.01%	133
2022 Q4	$126K	Buy	+1,607	New	+$119K	0.05%	105
2020 Q2	–	Sell	-269	Closed	-$15K	–	171
2020 Q1	$15K	Buy	+269	New	+$16.6K	0.01%	103
2014 Q3	–	Sell	-21,355	Closed	-$1.32M	–	337
2014 Q2	$1.32M	Buy	+21,355	New	+$1.27M	0.67%	48

Other funds holding PPH

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Avalon Trust Santa Fe, New Mexico $1.45B AUM 35.31% 1-Year Est. Return

JSAM

J. Safra Asset Management New York $1.86B AUM 22.95% 1-Year Est. Return

MTWSIF

Mivtachim The Workers Social Insurance Fund Tel Aviv, Israel $789M AUM 73.25% 1-Year Est. Return

MIM

Miller Investment Management West Conshohocken, Pennsylvania $1.01B AUM 13.96% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

AWC

Adamsbrown Wealth Consultants Wichita, Kansas $530M AUM 23.21% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Advisors Preferred's PPH Position: Q4 2024 in Review

Advisors Preferred sold out of VanEck Pharmaceutical ETF (PPH) in Q4 2024, closing a stake of 5,873 shares — an estimated $555K sold.

Advisors Preferred first reported a position in PPH in Q2 2014 and held it in 5 quarters. The position peaked at $1.32M in Q2 2014. 142 funds tracked by Wall St. Rank hold PPH as of Q4 2024.

Advisors Preferred reported no remaining VanEck Pharmaceutical ETF position as of Q4 2024 after selling out during the quarter.
Advisors Preferred sold 5,873 VanEck Pharmaceutical ETF shares in Q4 2024, an estimated $555K.
Advisors Preferred first reported a position in VanEck Pharmaceutical ETF in Q2 2014 and held it in 5 quarters.
Advisors Preferred's VanEck Pharmaceutical ETF position peaked at $1.32M in Q2 2014.
142 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q4 2024.

Based on Advisors Preferred's 13F filing for Q4 2024, filed 28 Jan 2025.